Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-­based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-­resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-­‐Mark for use in the GI tract, biliary and pancreatic ducts and lungs.
Paris, FR
Size (employees)
81 (est)-2%
Mauna Kea Technologies was founded in 2000 and is headquartered in Paris, FR
Report incorrect company information

Mauna Kea Technologies Office Locations

Mauna Kea Technologies has offices in Paris and Cambridge
Paris, FR (HQ)
9 Rue d'Enghien
Cambridge, US
210 185 Alewife Brook Pkwy
Show all (2)
Report incorrect company information

Mauna Kea Technologies Financials and Metrics

Mauna Kea Technologies Financials

Market capitalization (31-Oct-2017)

102.5 m

Closing share price (31-Oct-2017)

Mauna Kea Technologies's current market capitalization is €102.5 m.
Show all financial metrics
Report incorrect company information

Mauna Kea Technologies News and Updates

Report incorrect company information